Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy

Overview

The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyngeal cancer. Indeed, the level of knowledge about the consequences of oropharyngeal cancer treatment on sleep quality remains poor but the few studies published on the subject suggest an increased risk of development of OSAHS for these patients.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 30, 2021

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy.
    • Time Frame: Day 28
    • Number of patients with obstructive sleep apnea hypopnea syndrome after treatment combined chemoradiotherapy.

Secondary Measures

  • Severity of OSAHS as a function of the post-therapeutic delay.
    • Time Frame: Day 28
    • Value of the AHI as a function of the post-therapeutic delay which corresponds to the delay compared to the end of the curative treatment carried out for squamous cell carcinoma of the oropharynx. It is obtained after the inclusion visit and the realization of the polygraphy with the IAH score. OSAHS is mild (if IAH ≥ 5 / h and <15 / h), moderate (if IAH ≥ 15 / h and ≤ 30 / h) or severe (if IAH> 30 / h)

Participating in This Clinical Trial

Inclusion Criteria

  • Age> 18 years old – Performance Status 0-2 – Squamous cell carcinoma of the oropharynx treated with concomitant chemoradiotherapy – Treatment termination time greater than 6 months at inclusion – Tumor classification (American Joint Committee on Cancer 8th) T2-T4 N0-N3 – Patient in complete remission at inclusion – patient's consent's obtained after information Exclusion Criteria:

  • Previous treatment for upper aerodigestive tract cancer – Incomplete radiotherapyTreatment – Neurological pathology wich may affect the functions of the upper aerodigestive tract – Pregnant or breastfeeding woman – Unweaned alcoholism – Tracheotomized patient at the time of the study – Patient under protection: subjects with guardianship or under law protection – No health insurance coverage

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Poitiers University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Xavier DUFOUR, Pr, 05 49 44 33 89, xavier.dufour@chu-poitiers.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.